BRICS countries will create a barrier-free regulatory regime for biosimilars
Experts of the BRICS Working Group on Competition in Pharmaceutical Markets call for the removal of barriers to the regulation of the turnover of biological drugs and biosimilars in the BRICS+ countries
The HSE University BRICS Competition Law and Policy Centre (www.BRICSCompetition.org) has summarised the first results of its annual analytical study on bringing biotechnological drugs to the BRICS market. One of the conclusions of the report was the need to conduct a large-scale sectoral study on the removal of barriers in…